Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 7—July 2025

Research

Spatiotemporal Distribution and Clinical Characteristics of Zoonotic Tuberculosis, Spain, 2018–2022

Álvaro Roy, Diana Gómez-Barroso, Elena Cruz-Ferro, Ana Fernández, Isabel Martínez-Pino, María del Henar Marcos, Isabel Ursúa-Díaz, Susana Miras, Nuria Echave, Evi Ounarou, Beatriz Romero, Laura Herrera-León1, Zaida Herrador1Comments to Author , and Study Group on Zoonotic Tuberculosis2
Author affiliation: Instituto de Salud Carlos III, Madrid, Spain (Á. Roy, D. Gómez-Barroso, N. Echave, L. Herrera-León, Z. Herrador); CIBER in Epidemiology and Public Health, Madrid (D. Gómez-Barroso, I. Martínez-Pino, L. Herrera-León, Z. Herrador); Consejería de Sanidad Xunta de Galicia, Santiago de Compostela, Spain (E. Cruz-Ferro, I. Ursúa-Díaz, S. Miras); Consejería de Salud y Servicios Sanitarios Gobierno del Principado de Asturias, Oviedo, Spain (A. Fernández); Consejería de Sanidad Junta de Castilla y León, Valladolid, Spain (I. Martínez-Pino, M.H. Marcos); Aristotle University of Thessaloniki, Thessaloniki, Greece (E. Ounarou); VISAVET Health Surveillance Centre, Madrid (B. Romero); Complutense University of Madrid Faculty of Veterinary Medicine, Madrid (B. Romero)

Main Article

Table 1

Characteristics of patients with confirmed Mycobacterium caprae, M. bovis, and M. tuberculosis infection in study of tuberculosis, Spain, 2018–2022*

Category
 M. caprae, no. (%), n = 31
 M. bovis, no. (%), n = 218
M. tuberculosis, no. (%), n = 5,849
Age
0–19 3 (9.7) 20 (9.2) 355 (6.1)
20–39 10 (32.3) 38 (17.4) 1,834 (31.4)
40–59 5 (16.1) 49 (22.5) 1,951 (33.4)
60–79 10 (32.3) 70 (32.1) 1,113 (19.0)
80–99 3 (9.7) 41 (18.8) 593 (10.1)
Unknown
 0
 0
 3 (0.1)
Sex
M 25 (80.7) 143 (65.6) 3,796 (64.9)
F
 6 (19.4)
 75 (34.4)
 2,053 (35.1)
Country of birth
Other 6 (19.4) 54 (24.8) 2,133 (36.5)
Spain 25 (80.6) 136 (62.4) 2,426 (41.5)
Unknown
 0
 28 (12.8)
 1,290 (22.1)
Primary location
Pulmonary 16 (51.6) 115 (52.8) 4,460 (76.3)
Extrapulmonary 15 (48.4) 98 (45.0) 1,346 (23.0)
Unknown
 0
 5 (2.3)
 43 (0.7)
HIV laboratory result
Positive 3 (9.7) 3 (1.4) 368 (6.3)
Negative 18 (58.1) 146 (67.0) 3,713 (63.5)
Unknown
 10 (32.3)
 69 (31.7)
 1,738 (30.2)
Hospitalization
No 16 (51.6) 60 (27.5) 2,016 (35.4)
Yes 14 (45.2) 145 (66.5) 3,689 (63.1)
Unknown
 1 (3.2)
 13 (6.0)
 144 (2.5)
Treatment outcome
Complete/cure 26 (83.9) 147 (67.4) 3,563 (60.9)
Abandon/moved/loss 0 5 (2.3) 268 (4.6)
Death 2 (6.5) 27 (12.5) 500 (8.5)
Failure/prolongation 2 (6.5) 7 (3.2) 161 (2.8)
Unknown 1 (3.2) 32 (14.7) 1,357 (23.2)

*Treatment outcome was defined as follows: complete/cure, complete treatment or cure; abandon/moved/loss, abandonment of treatment, relocation, or loss of contact; death, death during treatment; failure/prolongation, treatment failure or patient still in treatment 12 mo after initiation.

Main Article

1These authors were co–principal investigators.

2Members of the group are listed at the end of this article.

Page created: May 31, 2025
Page updated: June 10, 2025
Page reviewed: June 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external